Download PDF
Semin Respir Crit Care Med
DOI: 10.1055/s-0044-1782653
Review Article

Systemic Lupus Erythematosus-related Lung Disease

Elisabeth Bendstrup
1   Center for Rare Lung Disease, Department of Respiratory Diseases and Allergy, Aarhus University Hospital, Aarhus, Denmark
2   Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
,
Evelyn Lynn
3   Department of Respiratory Medicine, St. Vincent's University Hospital, Dublin, Ireland
4   School of Medicine, University College Dublin, Dublin, Ireland
,
Anne Troldborg
2   Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
5   Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark
6   Biomedicine, Aarhus University, Aarhus, Denmark
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

Systemic Lupus Erythematosus (SLE) is a multifaceted, multisystem autoimmune disorder with diverse clinical expressions. While prevalence reports vary widely, pulmonary involvement accounts for significant morbidity and mortality in SLE. This comprehensive review explores the spectrum of pulmonary disease in SLE, including upper airway manifestations (e.g., laryngeal affection), lower airway conditions (e.g., bronchitis, bronchiolitis, bronchiectasis), parenchymal diseases (e.g., interstitial lung disease, acute lupus pneumonitis, diffuse alveolar hemorrhage), pleural diseases (e.g., serositis, shrinking lung syndrome), and vascular diseases (e.g., pulmonary arterial hypertension, pulmonary embolism, acute reversible hypoxemia syndrome). We discuss diagnostic modalities, treatment strategies, and prognosis for each pulmonary manifestation. With diagnostics remaining a challenge and with the absence of standardized treatment guidelines, we emphasize the need for evidence-based guidelines to optimize patient care and improve outcomes in this complex disease.

Keywords

systemic lupus erythematosus - acute lupus pneumonitis - alveolar hemorrhage - pleural effusion - serositis - shrinking lung syndrome - interstitial lung disease - pulmonary hypertension - pulmonary embolism


Publication History

Article published online:
28 March 2024

© 2024. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Kaul A, Gordon C, Crow MK. et al. Systemic lupus erythematosus. Nat Rev Dis Primers 2016; 2: 16039
    CrossrefPubMedGoogle Scholar
  • 2 Aringer M, Costenbader K, Daikh D. et al. 2019 EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol 2019; 71 (09) 1400
    CrossrefPubMedGoogle Scholar
  • 3 Aguilera-Pickens G, Abud-Mendoza C. Pulmonary manifestations in systemic lupus erythematosus: pleural involvement, acute pneumonitis, chronic interstitial lung disease and diffuse alveolar hemorrhage. Reumatol Clín (Engl Ed) 2018; 14 (05) 294-300
    CrossrefPubMedGoogle Scholar
  • 4 Osler W. On the visceral manifestations of the erythema group of skin diseases [Third Paper.] 1904. Am J Med Sci 2009; 338 (05) 396-408
    PubMedGoogle Scholar
  • 5 Tselios K, Urowitz MB. Cardiovascular and pulmonary manifestations of systemic lupus erythematosus. Curr Rheumatol Rev 2017; 13 (03) 206-218
    CrossrefPubMedGoogle Scholar
  • 6 Hannah JR, D'Cruz DP. Pulmonary complications of systemic lupus erythematosus. Semin Respir Crit Care Med 2019; 40 (02) 227-234
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Kamen DL, Strange C. Pulmonary manifestations of systemic lupus erythematosus. Clin Chest Med 2010; 31 (03) 479-488
    CrossrefPubMedGoogle Scholar
  • 8 Narváez J, Borrell H, Sánchez-Alonso F. et al; RELESSER Study Group. Primary respiratory disease in patients with systemic lupus erythematosus: data from the Spanish Rheumatology Society Lupus Registry (RELESSER) cohort. Arthritis Res Ther 2018; 20 (01) 280
    CrossrefPubMedGoogle Scholar
  • 9 Gladman DD, Urowitz MB, Caron D. et al. derivation of the sledai. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35 (06) 630-640
    PubMedGoogle Scholar
  • 10 Pines A, Kaplinsky N, Olchovsky D, Rozenman J, Frankl O. Pleuro-pulmonary manifestations of systemic lupus erythematosus: clinical features of its subgroups. Prognostic and therapeutic implications. Chest 1985; 88 (01) 129-135
    CrossrefPubMedGoogle Scholar
  • 11 Bertoli AM, Vila LM, Apte M. et al; LUMINA Study Group. Systemic lupus erythematosus in a multiethnic US Cohort LUMINA XLVIII: factors predictive of pulmonary damage. Lupus 2007; 16 (06) 410-417
    CrossrefPubMedGoogle Scholar
  • 12 Haye Salinas MJ, Caeiro F, Saurit V. et al; Grupo Latino Americano De Estudio del Lupus (GLADEL). Pleuropulmonary involvement in patients with systemic lupus erythematosus from a Latin American inception cohort (GLADEL). Lupus 2017; 26 (13) 1368-1377
    CrossrefPubMedGoogle Scholar
  • 13 Di Bartolomeo S, Alunno A, Carubbi F. Respiratory manifestations in systemic lupus erythematosus. Pharmaceuticals (Basel) 2021; 14 (03) 276
    CrossrefPubMedGoogle Scholar
  • 14 Lee JH, Sung IY, Park JH, Roh JL. Recurrent laryngeal neuropathy in a systemic lupus erythematosus (SLE) patient. Am J Phys Med Rehabil 2008; 87 (01) 68-70
    CrossrefPubMedGoogle Scholar
  • 15 Teitel AD, MacKenzie CR, Stern R, Paget SA. Laryngeal involvement in systemic lupus erythematosus. Semin Arthritis Rheum 1992; 22 (03) 203-214
    CrossrefPubMedGoogle Scholar
  • 16 Karim A, Ahmed S, Siddiqui R, Marder GS, Mattana J. Severe upper airway obstruction from cricoarytenoiditis as the sole presenting manifestation of a systemic lupus erythematosus flare. Chest 2002; 121 (03) 990-993
    CrossrefPubMedGoogle Scholar
  • 17 Schwartz IS, Grishman E. Rheumatoid nodules of the vocal cords as the initial manifestation of systemic lupus erythematosus. JAMA 1980; 244 (24) 2751-2752
    CrossrefPubMedGoogle Scholar
  • 18 Wohlgelernter D, Loke J, Matthay RA, Siegel NJ. Systemic and discoid lupus erythematosus: analysis of pulmonary function. Yale J Biol Med 1978; 51 (02) 157-164
    PubMedGoogle Scholar
  • 19 Andonopoulos AP, Constantopoulos SH, Galanopoulou V, Drosos AA, Acritidis NC, Moutsopoulos HM. Pulmonary function of nonsmoking patients with systemic lupus erythematosus. Chest 1988; 94 (02) 312-315
    CrossrefPubMedGoogle Scholar
  • 20 Carmier D, Marchand-Adam S, Diot P, Diot E. Respiratory involvement in systemic lupus erythematosus. Rev Mal Respir 2010; 27 (08) e66-e78
    CrossrefPubMedGoogle Scholar
  • 21 Kinney WW, Angelillo VA. Bronchiolitis in systemic lupus erythematosus. Chest 1982; 82 (05) 646-649
    CrossrefPubMedGoogle Scholar
  • 22 Carmier D, Marchand-Adam S, Diot P, Diot E. [Respiratory involvement in systemic lupus erythematosus]. Rev Mal Respir 2008; 25 (10) 1289-1303
    PubMedGoogle Scholar
  • 23 Luo Y, Fan X, Jiang C. et al. Systemic lupus erythematosus and angioedema: a cross-sectional study from the national inpatient sample. Arch Rheumatol 2019; 34 (03) 301-307
    CrossrefPubMedGoogle Scholar
  • 24 Kumar N, Surendran D, Bammigatti C. Angioedema as the presenting feature of systemic lupus erythematosus. BMJ Case Rep 2018; 2018: bcr2018224222
    CrossrefPubMedGoogle Scholar
  • 25 Todic J, Leuchter I. Lupus of the larynx: when bamboo nodes lead to diagnosis…. BMJ Case Rep 2018; 2018: bcr2017221652
    CrossrefPubMedGoogle Scholar
  • 26 Bankier AA, Kiener HP, Wiesmayr MN. et al. Discrete lung involvement in systemic lupus erythematosus: CT assessment. Radiology 1995; 196 (03) 835-840
    CrossrefPubMedGoogle Scholar
  • 27 Ooi GC, Ngan H, Peh WCG, Mok MY, Ip M. Systemic lupus erythematosus patients with respiratory symptoms: the value of HRCT. Clin Radiol 1997; 52 (10) 775-781
    CrossrefPubMedGoogle Scholar
  • 28 Fenlon HM, Doran M, Sant SM, Breatnach E. High-resolution chest CT in systemic lupus erythematosus. AJR Am J Roentgenol 1996; 166 (02) 301-307
    CrossrefPubMedGoogle Scholar
  • 29 Silberstein SL, Barland P, Grayzel AI, Koerner SK. Pulmonary dysfunction in systemic lupus erythematosus:prevalence classification and correlation with other organ involvement. J Rheumatol 1980; 7 (02) 187-195
    PubMedGoogle Scholar
  • 30 Eichacker PQ, Pinsker K, Epstein A, Schiffenbauer J, Grayzel A. Serial pulmonary function testing in patients with systemic lupus erythematosus. Chest 1988; 94 (01) 129-132
    CrossrefPubMedGoogle Scholar
  • 31 Rolla G, Brussino L, Bertero MT, Bucca C, Converso M, Caligaris-Cappio F. Respiratory function in systemic lupus erythematosus: relation with activity and severity. Lupus 1996; 5 (01) 38-43
    CrossrefPubMedGoogle Scholar
  • 32 Mageau A, Borie R, Crestani B, Timsit JF, Papo T, Sacre K. Epidemiology of interstitial lung disease in systemic lupus erythematosus in France: a nation-wide population-based study over 10 years. Respirology 2022; 27 (08) 630-634
    CrossrefPubMedGoogle Scholar
  • 33 Weinrib L, Sharma OP, Quismorio Jr FP. A long-term study of interstitial lung disease in systemic lupus erythematosus. Semin Arthritis Rheum 1990; 20 (01) 48-56
    CrossrefPubMedGoogle Scholar
  • 34 Enomoto N, Egashira R, Tabata K. et al. Analysis of systemic lupus erythematosus-related interstitial pneumonia: a retrospective multicentre study. Sci Rep 2019; 9 (01) 7355
    CrossrefPubMedGoogle Scholar
  • 35 Sahu D, Saha S, Bhattacherjee S, Datta S, Banik S. Pulmonary involvement in systemic lupus erythematosus patients in a tertiary care hospital. J Assoc Physicians India 2022; 70 (12) 11-12
    PubMedGoogle Scholar
  • 36 Haupt HM, Moore GW, Hutchins GM. The lung in systemic lupus erythematosus. Analysis of the pathologic changes in 120 patients. Am J Med 1981; 71 (05) 791-798
    CrossrefPubMedGoogle Scholar
  • 37 Kondoh Y, Makino S, Ogura T. et al; Joint Committee of Japanese Respiratory Society and Japan College of Rheumatology. 2020 guide for the diagnosis and treatment of interstitial lung disease associated with connective tissue disease. Respir Investig 2021; 59 (06) 709-740
    CrossrefPubMedGoogle Scholar
  • 38 Flaherty KR, Wells AU, Cottin V. et al; INBUILD Trial Investigators. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med 2019; 381 (18) 1718-1727
    CrossrefPubMedGoogle Scholar
  • 39 Wan SA, Teh CL, Jobli AT. Lupus pneumonitis as the initial presentation of systemic lupus erythematosus: case series from a single institution. Lupus 2016; 25 (13) 1485-1490
    CrossrefPubMedGoogle Scholar
  • 40 Matthay RA, Schwarz MI, Petty TL. et al. Pulmonary manifestations of systemic lupus erythematosus: review of twelve cases of acute lupus pneumonitis. Medicine (Baltimore) 1975; 54 (05) 397-409
    CrossrefPubMedGoogle Scholar
  • 41 Crestani B. The respiratory system in connective tissue disorders. Allergy 2005; 60 (06) 715-734
    CrossrefPubMedGoogle Scholar
  • 42 Chetan G, Mahadevan S, Sulanthung K, Narayanan P. Intravenous immunoglobulin therapy of lupus pneumonitis. Indian J Pediatr 2007; 74 (11) 1032-1033
    CrossrefPubMedGoogle Scholar
  • 43 Lim SW, Gillis D, Smith W, Hissaria P, Greville H, Peh CA. Rituximab use in systemic lupus erythematosus pneumonitis and a review of current reports. Intern Med J 2006; 36 (04) 260-262
    CrossrefPubMedGoogle Scholar
  • 44 Law AHN, Chuah TY, Lee W. et al. Diffuse alveolar haemorrhage in systemic lupus erythematosus: a multicentre retrospective study in Singapore. Lupus 2023; 32 (08) 952-963
    CrossrefPubMedGoogle Scholar
  • 45 Kim D, Choi J, Cho SK. et al. Clinical characteristics and outcomes of diffuse alveolar hemorrhage in patients with systemic lupus erythematosus. Semin Arthritis Rheum 2017; 46 (06) 782-787
    CrossrefPubMedGoogle Scholar
  • 46 Andrade C, Mendonça T, Farinha F. et al. Alveolar hemorrhage in systemic lupus erythematosus: a cohort review. Lupus 2016; 25 (01) 75-80
    CrossrefPubMedGoogle Scholar
  • 47 Xu T, Zhang G, Lin H. et al. Clinical characteristics and risk factors of diffuse alveolar hemorrhage in systemic lupus erythematosus: a systematic review and meta-analysis based on observational studies. Clin Rev Allergy Immunol 2020; 59 (03) 295-303
    CrossrefPubMedGoogle Scholar
  • 48 Kwok SK, Moon SJ, Ju JH. et al. Diffuse alveolar hemorrhage in systemic lupus erythematosus: risk factors and clinical outcome: results from affiliated hospitals of Catholic University of Korea. Lupus 2011; 20 (01) 102-107
    CrossrefPubMedGoogle Scholar
  • 49 Martinez-Martinez MU, Sturbaum AK, Alcocer-Varela J. et al. Factors associated with mortality and infections in patients with systemic lupus erythematosus with diffuse alveolar hemorrhage. J Rheumatol 2014; 41 (08) 1656-1661
    CrossrefPubMedGoogle Scholar
  • 50 Rojas-Serrano J, Pedroza J, Regalado J. et al. High prevalence of infections in patients with systemic lupus erythematosus and pulmonary haemorrhage. Lupus 2008; 17 (04) 295-299
    CrossrefPubMedGoogle Scholar
  • 51 Pego-Reigosa JM, Medeiros DA, Isenberg DA. Respiratory manifestations of systemic lupus erythematosus: old and new concepts. Best Pract Res Clin Rheumatol 2009; 23 (04) 469-480
    CrossrefPubMedGoogle Scholar
  • 52 Good Jr JT, King TE, Antony VB, Sahn SA. Lupus pleuritis. Clinical features and pleural fluid characteristics with special reference to pleural fluid antinuclear antibodies. Chest 1983; 84 (06) 714-718
    PubMedGoogle Scholar
  • 53 Choi BY, Yoon MJ, Shin K, Lee YJ, Song YW. Characteristics of pleural effusions in systemic lupus erythematosus: differential diagnosis of lupus pleuritis. Lupus 2015; 24 (03) 321-326
    CrossrefPubMedGoogle Scholar
  • 54 Amarnani R, Yeoh SA, Denneny EK, Wincup C. Lupus and the lungs: the assessment and management of pulmonary manifestations of systemic lupus erythematosus. Front Med (Lausanne) 2021; 7: 610257
    CrossrefPubMedGoogle Scholar
  • 55 Wang DY. Diagnosis and management of lupus pleuritis. Curr Opin Pulm Med 2002; 8 (04) 312-316
    CrossrefPubMedGoogle Scholar
  • 56 Alamoudi OSB, Attar SM. Pulmonary manifestations in systemic lupus erythematosus: association with disease activity. Respirology 2015; 20 (03) 474-480
    CrossrefPubMedGoogle Scholar
  • 57 Sharma S, Smith R, Al-Hameed F. Fibrothorax and severe lung restriction secondary to lupus pleuritis and its successful treatment by pleurectomy. Can Respir J 2002; 9 (05) 335-337
    CrossrefPubMedGoogle Scholar
  • 58 Palavutitotai N, Buppajarntham T, Katchamart W. Etiologies and outcomes of pleural effusions in patients with systemic lupus erythematosus. J Clin Rheumatol 2014; 20 (08) 418-421
    CrossrefPubMedGoogle Scholar
  • 59 Fanouriakis A, Kostopoulou M, Andersen J. et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis 2024; 83 (01) 15-29
    CrossrefPubMedGoogle Scholar
  • 60 McKnight KM, Adair NE, Agudelo CA. Successful use of tetracycline pleurodesis to treat massive pleural effusion secondary to systemic lupus erythematosus. Arthritis Rheum 1991; 34 (11) 1483-1484
    CrossrefPubMedGoogle Scholar
  • 61 Glazer M, Berkman N, Lafair JS, Kramer MR. Successful talc slurry pleurodesis in patients with nonmalignant pleural effusion. Chest 2000; 117 (05) 1404-1409
    CrossrefPubMedGoogle Scholar
  • 62 Hoffbrand BI, Beck ER. “Unexplained” dyspnoea and shrinking lungs in systemic lupus erythematosus. BMJ 1965; 1 (5445) 1273-1277
    CrossrefPubMedGoogle Scholar
  • 63 Duron L, Cohen-Aubart F, Diot E. et al. Shrinking lung syndrome associated with systemic lupus erythematosus: a multicenter collaborative study of 15 new cases and a review of the 155 cases in the literature focusing on treatment response and long-term outcomes. Autoimmun Rev 2016; 15 (10) 994-1000
    CrossrefPubMedGoogle Scholar
  • 64 Toya SP, Tzelepis GE. Association of the shrinking lung syndrome in systemic lupus erythematosus with pleurisy: a systematic review. Semin Arthritis Rheum 2009; 39 (01) 30-37
    CrossrefPubMedGoogle Scholar
  • 65 Chick TW, DeHoratius RJ, Skipper BE, Messner RP. Pulmonary dysfunction in systemic lupus erythematosus without pulmonary symptoms. J Rheumatol 1976; 3 (03) 262-268
    PubMedGoogle Scholar
  • 66 Almajed MR, Obri MS, Mahmood S, Demertzis ZD. Shrinking lung syndrome in a young female: a rare pulmonary manifestation of systemic lupus erythematosus. Cureus 2022; 14 (04) e24320
    PubMedGoogle Scholar
  • 67 Tavoni A, Vitali C, Cirigliano G, Frigelli S, Stampacchia G, Bombardieri S. Shrinking lung in primary Sjögren's syndrome. Arthritis Rheum 1999; 42 (10) 2249-2250
    CrossrefPubMedGoogle Scholar
  • 68 Ahmed S, Herrick A, O'Driscoll BR. Shrinking lung syndrome in patients without systemic lupus erythematosus: comment on the concise communication by Tavoni et al. Arthritis Rheum 2001; 44 (01) 243-245
    CrossrefPubMedGoogle Scholar
  • 69 Singh R, Huang W, Menon Y, Espinoza LR. Shrinking lung syndrome in systemic lupus erythematosus and Sjogren's syndrome. J Clin Rheumatol 2002; 8 (06) 340-345
    CrossrefPubMedGoogle Scholar
  • 70 Scirè CA, Caporali R, Zanierato M, Mojoli F, Braschi A, Montecucco C. Shrinking lung syndrome in systemic sclerosis. Arthritis Rheum 2003; 48 (10) 2999-3000
    CrossrefPubMedGoogle Scholar
  • 71 Calderaro DC, Ferreira GA. Presentation and prognosis of shrinking lung syndrome in systemic lupus erythematosus: report of four cases. Rheumatol Int 2012; 32 (05) 1391-1396
    CrossrefPubMedGoogle Scholar
  • 72 Warrington KJ, Moder KG, Brutinel WM. The shrinking lungs syndrome in systemic lupus erythematosus. Mayo Clin Proc 2000; 75 (05) 467-472
    CrossrefPubMedGoogle Scholar
  • 73 Hardy K, Herry I, Attali V, Cadranel J, Similowski T. Bilateral phrenic paralysis in a patient with systemic lupus erythematosus. Chest 2001; 119 (04) 1274-1277
    CrossrefPubMedGoogle Scholar
  • 74 Pérez-de-Llano LA, Castro-Añón O, López MJ, Escalona E, Teijeira S, Sánchez-Andrade A. Shrinking lung syndrome caused by lupus myopathy. QJM 2011; 104 (03) 259-262
    CrossrefPubMedGoogle Scholar
  • 75 Rubin LA, Urowitz MB. Shrinking lung syndrome in SLE–a clinical pathologic study. J Rheumatol 1983; 10 (06) 973-976
    PubMedGoogle Scholar
  • 76 Laroche CM, Mulvey DA, Hawkins PN. et al. Diaphragm strength in the shrinking lung syndrome of systemic lupus erythematosus. Q J Med 1989; 71 (265) 429-439
    PubMedGoogle Scholar
  • 77 Hawkins P, Davison AG, Dasgupta B, Moxham J. Diaphragm strength in acute systemic lupus erythematosus in a patient with paradoxical abdominal motion and reduced lung volumes. Thorax 2001; 56 (04) 329-330
    CrossrefPubMedGoogle Scholar
  • 78 Omdal R, Roos P, Wildhagen K, Gunnarsson R. Respiratory arrest in systemic lupus erythematosus due to phrenic nerve neuropathy. Lupus 2004; 13 (10) 817-819
    CrossrefPubMedGoogle Scholar
  • 79 Wilcox PG, Stein HB, Clarke SD, Paré PD, Pardy RL. Phrenic nerve function in patients with diaphragmatic weakness and systemic lupus erythematosus. Chest 1988; 93 (02) 352-358
    CrossrefPubMedGoogle Scholar
  • 80 Roy F, Korathanakhun P, Karamchandani J. et al. Myositis with prominent B-cell aggregates causing shrinking lung syndrome in systemic lupus erythematosus: a case report. BMC Rheumatol 2022; 6 (01) 11
    CrossrefPubMedGoogle Scholar
  • 81 Weissman BA, Fatt I. Cancellation of the boundary and edge effects by choice of lens thickness during oxygen permeability measurement of contact lenses. Optom Vis Sci 1989; 66 (05) 264-268
    CrossrefPubMedGoogle Scholar
  • 82 Karim MY, Miranda LC, Tench CM. et al. Presentation and prognosis of the shrinking lung syndrome in systemic lupus erythematosus. Semin Arthritis Rheum 2002; 31 (05) 289-298
    CrossrefPubMedGoogle Scholar
  • 83 Satış H, Cindil E, Salman RB. et al. Diaphragmatic muscle thickness and diaphragmatic function are reduced in patients with systemic lupus erythematosus compared to those with primary Sjögren's syndrome. Lupus 2020; 29 (07) 715-720
    CrossrefPubMedGoogle Scholar
  • 84 Borrell H, Narváez J, Alegre JJ. et al. Shrinking lung syndrome in systemic lupus erythematosus: a case series and review of the literature. Medicine (Baltimore) 2016; 95 (33) e4626
    CrossrefPubMedGoogle Scholar
  • 85 Langenskiöld E, Bonetti A, Fitting JW. et al. Shrinking lung syndrome successfully treated with rituximab and cyclophosphamide. Respiration 2012; 84 (02) 144-149
    CrossrefPubMedGoogle Scholar
  • 86 Pillai S, Mehta J, Levin T, Muzumdar H, Nandalike K. Shrinking lung syndrome presenting as an initial pulmonary manifestation of SLE. Lupus 2014; 23 (11) 1201-1203
    CrossrefPubMedGoogle Scholar
  • 87 Humbert M, Kovacs G, Hoeper MM. et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2023;61(01):
    PubMedGoogle Scholar
  • 88 Johnson SR, Gladman DD, Urowitz MB, Ibañez D, Granton JT. Pulmonary hypertension in systemic lupus. Lupus 2004; 13 (07) 506-509
    CrossrefPubMedGoogle Scholar
  • 89 Pan TL, Thumboo J, Boey ML. Primary and secondary pulmonary hypertension in systemic lupus erythematosus. Lupus 2000; 9 (05) 338-342
    CrossrefPubMedGoogle Scholar
  • 90 Quismorio Jr FP, Sharma O, Koss M. et al. Immunopathologic and clinical studies in pulmonary hypertension associated with systemic lupus erythematosus. Semin Arthritis Rheum 1984; 13 (04) 349-359
    CrossrefPubMedGoogle Scholar
  • 91 Shen JY, Chen SL, Wu YX. et al. Pulmonary hypertension in systemic lupus erythematosus. Rheumatol Int 1999; 18 (04) 147-151
    CrossrefPubMedGoogle Scholar
  • 92 Simonson JS, Schiller NB, Petri M, Hellmann DB. Pulmonary hypertension in systemic lupus erythematosus. J Rheumatol 1989; 16 (07) 918-925
    PubMedGoogle Scholar
  • 93 Winslow TM, Ossipov MA, Fazio GP, Simonson JS, Redberg RF, Schiller NB. Five-year follow-up study of the prevalence and progression of pulmonary hypertension in systemic lupus erythematosus. Am Heart J 1995; 129 (03) 510-515
    CrossrefPubMedGoogle Scholar
  • 94 Dhala A. Pulmonary arterial hypertension in systemic lupus erythematosus: current status and future direction. Clin Dev Immunol 2012; 2012: 854941
    CrossrefPubMedGoogle Scholar
  • 95 Prabu A, Patel K, Yee CS. et al. Prevalence and risk factors for pulmonary arterial hypertension in patients with lupus. Rheumatology (Oxford) 2009; 48 (12) 1506-1511
    CrossrefPubMedGoogle Scholar
  • 96 Lv TT, Wang P, Guan SY. et al. Prevalence of pulmonary hypertension in systemic lupus erythematosus: a meta-analysis. Ir J Med Sci 2018; 187 (03) 723-730
    CrossrefPubMedGoogle Scholar
  • 97 Li EK, Tam LS. Pulmonary hypertension in systemic lupus erythematosus: clinical association and survival in 18 patients. J Rheumatol 1999; 26 (09) 1923-1929
    PubMedGoogle Scholar
  • 98 Pope J. An update in pulmonary hypertension in systemic lupus erythematosus - do we need to know about it?. Lupus 2008; 17 (04) 274-277
    CrossrefPubMedGoogle Scholar
  • 99 Depascale R, Del Frate G, Gasparotto M. et al. Diagnosis and management of lung involvement in systemic lupus erythematosus and Sjögren's syndrome: a literature review. Ther Adv Musculoskelet Dis 2021; 13: X211040696
    CrossrefPubMedGoogle Scholar
  • 100 Tselios K, Gladman DD, Urowitz MB. Systemic lupus erythematosus and pulmonary arterial hypertension: links, risks, and management strategies. Open Access Rheumatol 2016; 9: 1-9
    CrossrefPubMedGoogle Scholar
  • 101 Kim KJ, Baek IW, Park YJ, Yoon CH, Kim WU, Cho CS. High levels of uric acid in systemic lupus erythematosus is associated with pulmonary hypertension. Int J Rheum Dis 2015; 18 (05) 524-532
    CrossrefPubMedGoogle Scholar
  • 102 Hoeper MM, Bogaard HJ, Condliffe R. et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 2013; 62 (25) D42-D50
    CrossrefPubMedGoogle Scholar
  • 103 Badesch DB, Hill NS, Burgess G. et al; SUPER Study Group. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheumatol 2007; 34 (12) 2417-2422
    PubMedGoogle Scholar
  • 104 Mok MY, Tsang PL, Lam YM, Lo Y, Wong WS, Lau CS. Bosentan use in systemic lupus erythematosus patients with pulmonary arterial hypertension. Lupus 2007; 16 (04) 279-285
    CrossrefPubMedGoogle Scholar
  • 105 Oudiz RJ, Schilz RJ, Barst RJ. et al; Treprostinil Study Group. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest 2004; 126 (02) 420-427
    CrossrefPubMedGoogle Scholar
  • 106 Robbins IM, Gaine SP, Schilz R, Tapson VF, Rubin LJ, Loyd JE. Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus. Chest 2000; 117 (01) 14-18
    CrossrefPubMedGoogle Scholar
  • 107 Rubin LJ, Badesch DB, Barst RJ. et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346 (12) 896-903
    CrossrefPubMedGoogle Scholar
  • 108 Shirai Y, Yasuoka H, Takeuchi T, Satoh T, Kuwana M. Intravenous epoprostenol treatment of patients with connective tissue disease and pulmonary arterial hypertension at a single center. Mod Rheumatol 2013; 23 (06) 1211-1220
    CrossrefPubMedGoogle Scholar
  • 109 Humbert M, Coghlan JG, Ghofrani HA. et al. Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2. Ann Rheum Dis 2017; 76 (02) 422-426
    CrossrefPubMedGoogle Scholar
  • 110 Kuzuya K, Tsuji S, Matsushita M, Ohshima S, Saeki Y. Systemic sclerosis and systemic lupus erythematosus overlap syndrome with pulmonary arterial hypertension successfully treated with immunosuppressive therapy and riociguat. Cureus 2019; 11 (03) e4327
    PubMedGoogle Scholar
  • 111 Gonzalez-Lopez L, Cardona-Muñoz EG, Celis A. et al. Therapy with intermittent pulse cyclophosphamide for pulmonary hypertension associated with systemic lupus erythematosus. Lupus 2004; 13 (02) 105-112
    CrossrefPubMedGoogle Scholar
  • 112 Kommireddy S, Bhyravavajhala S, Kurimeti K. et al. Pulmonary arterial hypertension in systemic lupus erythematosus may benefit by addition of immunosuppression to vasodilator therapy: an observational study. Rheumatology (Oxford) 2015; 54 (09) 1673-1679
    CrossrefPubMedGoogle Scholar
  • 113 Prete M, Fatone MC, Vacca A, Racanelli V, Perosa F. Severe pulmonary hypertension as the initial manifestation of systemic lupus erythematosus: a case report and review of the literature. Clin Exp Rheumatol 2014; 32 (02) 267-274
    PubMedGoogle Scholar
  • 114 Tanaka E, Harigai M, Tanaka M, Kawaguchi Y, Hara M, Kamatani N. Pulmonary hypertension in systemic lupus erythematosus: evaluation of clinical characteristics and response to immunosuppressive treatment. J Rheumatol 2002; 29 (02) 282-287
    PubMedGoogle Scholar
  • 115 Yusuf HR, Hooper WC, Grosse SD, Parker CS, Boulet SL, Ortel TL. Risk of venous thromboembolism occurrence among adults with selected autoimmune diseases: a study among a U.S. cohort of commercial insurance enrollees. Thromb Res 2015; 135 (01) 50-57
    CrossrefPubMedGoogle Scholar
  • 116 Yusuf HR, Hooper WC, Beckman MG, Zhang QC, Tsai J, Ortel TL. Risk of venous thromboembolism among hospitalizations of adults with selected autoimmune diseases. J Thromb Thrombolysis 2014; 38 (03) 306-313
    CrossrefPubMedGoogle Scholar
  • 117 Calvo-Alén J, Toloza SMA, Fernández M. et al; LUMINA Study Group. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXV. Smoking, older age, disease activity, lupus anticoagulant, and glucocorticoid dose as risk factors for the occurrence of venous thrombosis in lupus patients. Arthritis Rheum 2005; 52 (07) 2060-2068
    CrossrefPubMedGoogle Scholar
  • 118 Wahl DG, Guillemin F, de Maistre E, Perret C, Lecompte T, Thibaut G. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus–a meta-analysis. Lupus 1997; 6 (05) 467-473
    CrossrefPubMedGoogle Scholar
  • 119 Pengo V, Denas G, Zoppellaro G. et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood 2018; 132 (13) 1365-1371
    CrossrefPubMedGoogle Scholar
  • 120 Abramson SB, Dobro J, Eberle MA. et al. Acute reversible hypoxemia in systemic lupus erythematosus. Ann Intern Med 1991; 114 (11) 941-947
    CrossrefPubMedGoogle Scholar
  • 121 Martinez-Taboada VM, Blanco R, Armona J, Fernandez-Sueiro JL, Rodriguez-Valverde V. Acute reversible hypoxemia in systemic lupus erythematosus: a new syndrome or an index of disease activity?. Lupus 1995; 4 (04) 259-262
    CrossrefPubMedGoogle Scholar
  • 122 Keane MP, Lynch III JP. Pleuropulmonary manifestations of systemic lupus erythematosus. Thorax 2000; 55 (02) 159-166
    CrossrefPubMedGoogle Scholar
  • 123 McCool FD, Tzelepis GE. Dysfunction of the diaphragm. N Engl J Med 2012; 366 (10) 932-942
    CrossrefPubMedGoogle Scholar
  • 124 Dubé BP, Dres M. Diaphragm dysfunction: diagnostic approaches and management strategies. J Clin Med 2016; 5 (12) 113
    CrossrefPubMedGoogle Scholar
  • 125 Mansel JK, Norman JR. Respiratory complications and management of spinal cord injuries. Chest 1990; 97 (06) 1446-1452
    CrossrefPubMedGoogle Scholar
  • 126 Borel CO, Guy J. Ventilatory management in critical neurologic illness. Neurol Clin 1995; 13 (03) 627-644
    CrossrefPubMedGoogle Scholar
  • 127 Laroche CM, Green M. The diaphragm in SLE. Chest 1988; 94 (05) 1115
    CrossrefPubMedGoogle Scholar
  • 128 Torrente-Segarra V, Salman-Monte TC, Rúa-Figueroa Í. et al; RELESSER Study Group of the Spanish Society of Rheumatology (SER) and the Study Group of Systemic Autoimmune Diseases of the SER (EAS-SER). Associated factors to serious infections in a large cohort of juvenile-onset systemic lupus erythematosus from Lupus Registry (RELESSER). Semin Arthritis Rheum 2020; 50 (04) 657-662
    CrossrefPubMedGoogle Scholar
  • 129 Schurder J, Goulenok T, Jouenne R. et al. Pneumococcal infection in patients with systemic lupus erythematosus. Joint Bone Spine 2018; 85 (03) 333-336
    CrossrefPubMedGoogle Scholar
  • 130 Peng L, Wang Y, Zhao L, Chen T, Huang A. Severe pneumonia in Chinese patients with systemic lupus erythematosus. Lupus 2020; 29 (07) 735-742
    CrossrefPubMedGoogle Scholar
  • 131 Luijten RKMAC, Cuppen BVJ, Bijlsma JWJ, Derksen RHWM. Serious infections in systemic lupus erythematosus with a focus on pneumococcal infections. Lupus 2014; 23 (14) 1512-1516
    CrossrefPubMedGoogle Scholar
  • 132 Landewé RBM, Kroon FPB, Alunno A. et al. EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update. Ann Rheum Dis 2022; 81 (12) 1628-1639
    CrossrefPubMedGoogle Scholar
  • 133 Furer V, Rondaan C, Heijstek MW. et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2020; 79 (01) 39-52
    CrossrefPubMedGoogle Scholar
  • 134 Spagnolo P, Bonniaud P, Rossi G, Sverzellati N, Cottin V. Drug-induced interstitial lung disease. Eur Respir J 2022; 60 (04) 2102776
    CrossrefPubMedGoogle Scholar
  • 135 Petri M, Orbai A-M, Alarcón GS. et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64 (08) 2677-2686
    CrossrefPubMedGoogle Scholar
  • 136 Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. The Committee on Prognosis Studies in SLE. Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum 1992; 35 (06) 630-640
    CrossrefPubMedGoogle Scholar